Indications
Renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Composition
- Active substance
- sevelamer
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Renagel
- Active substance
- sevelamer
- ATC code
- V03AE02
- Group
- Various
- Therapeutic area
- Renal Dialysis, Hyperphosphatemia
- Marketing authorisation holder
- Sanofi Winthrop Industrie